Vertex Pharmaceuticals Inc has gained US approval for the first new type of painkiller in more than two decades, paving the way for a safer alternative to addictive opioids that have been linked to hundreds of thousands of deaths.
Vertex’s pill, called Journavx, received US Food and Drug Administration clearance to treat moderate to severe acute pain, a statement said on Thursday. The wholesale acquisition cost for the twice-daily medicine is set at US$15.50 per 50 milligram tablet, Vertex said.
Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures. More than half a million US deaths were linked to overdoses of the addictive drugs from 1999 to 2019, official figures show, with more than 70,000 in the year through June last year alone.
Photo:AP
While some fatalities involved use of illicit drugs, many people begin taking them after they lost access to prescribed opioids, leading doctors and health officials to look for other options.
Vertex’s drug has been hailed as a scientific breakthrough, because it allays pain without entering the brain, minimizing the risk of addiction and dependence that can lead patients to ramp up doses to dangerous levels. It is a key to Vertex’s strategy of diversifying beyond its core business centered on cystic fibrosis treatments.
While some analysts predict the painkiller would become a multibillion-dollar product for a company needing a growth driver, questions remain about its price and commercial potential. Health insurers and hospitals might continue steering patients to opioids, which — while dangerous — are cheap and effective.
Vertex has been pressing Congress to create policies that would help its product succeed. For example, the No Pain Act, which provides extra Medicare reimbursement to hospitals that prescribe alternatives to opioids, went into effect this year.
The company plans to focus on selling its drug to the about 2,000 US hospitals that see about two-thirds of patients in acute pain, chief operating officer Stuart Arbuckle said.
Boston-based Vertex, the maker of cystic fibrosis treatments like the blockbuster Trikafta, has worked for more than two decades to develop a nonaddictive pain drug. Journavx, also called suzetrigine, blocks a structure in the nerve cells that send pain signals to the brain.
In late-stage studies of patients with acute pain after surgery, Vertex’s drug worked better than a placebo, but failed to reduce pain faster than a combination of acetaminophen, better known as Tylenol, and an opioid. That could present a challenge for Vertex, as new drugs typically must outperform what is already on the market to gain traction.
Vertex is studying the same pill to treat chronic pain lasting at least three months, which affects about 50 million Americans. The company encountered a setback in December when a mid-stage trial showed the drug failed to work better than a placebo in lower back pain, causing the shares to plunge.
VAGUE: The criteria of the amnesty remain unclear, but it would cover political violence from 1999 to today, and those convicted of murder or drug trafficking would not qualify Venezuelan Acting President Delcy Rodriguez on Friday announced an amnesty bill that could lead to the release of hundreds of prisoners, including opposition leaders, journalists and human rights activists detained for political reasons. The measure had long been sought by the US-backed opposition. It is the latest concession Rodriguez has made since taking the reins of the country on Jan. 3 after the brazen seizure of then-Venezuelan president Nicolas Maduro. Rodriguez told a gathering of justices, magistrates, ministers, military brass and other government leaders that the ruling party-controlled Venezuelan National Assembly would take up the bill with urgency. Rodriguez also announced the shutdown
Civil society leaders and members of a left-wing coalition yesterday filed impeachment complaints against Philippine Vice President Sara Duterte, restarting a process sidelined by the Supreme Court last year. Both cases accuse Duterte of misusing public funds during her term as education secretary, while one revives allegations that she threatened to assassinate former ally Philippine President Ferdinand Marcos Jr. The filings come on the same day that a committee in the House of Representatives was to begin hearings into impeachment complaints against Marcos, accused of corruption tied to a spiraling scandal over bogus flood control projects. Under the constitution, an impeachment by the
Exiled Tibetans began a unique global election yesterday for a government representing a homeland many have never seen, as part of a democratic exercise voters say carries great weight. From red-robed Buddhist monks in the snowy Himalayas, to political exiles in megacities across South Asia, to refugees in Australia, Europe and North America, voting takes place in 27 countries — but not China. “Elections ... show that the struggle for Tibet’s freedom and independence continues from generation to generation,” said candidate Gyaltsen Chokye, 33, who is based in the Indian hill-town of Dharamsala, headquarters of the government-in-exile, the Central Tibetan Administration (CTA). It
A Virginia man having an affair with the family’s Brazilian au pair on Monday was found guilty of murdering his wife and another man that prosecutors say was lured to the house as a fall guy. Brendan Banfield, a former Internal Revenue Service law enforcement officer, told police he came across Joseph Ryan attacking his wife, Christine Banfield, with a knife on the morning of Feb. 24, 2023. He shot Ryan and then Juliana Magalhaes, the au pair, shot him, too, but officials argued in court that the story was too good to be true, telling jurors that Brendan Banfield set
RSS